Photo: Mark via Flickr
Hospitals have been merging and acquiring physician practices at a breakneck pace. They say it’s what they have to do to save money on big-ticket items like health care information technology, and to move toward the coordinated care models encouraged by the Affordable Care Act.
But insurers, state attorneys general and federal antitrust enforcers have a different take. They say consolidation can give hospitals monopoly power to drive up prices and hurt consumers. Continue reading
It’s put up or shut up time for Bayer Healthcare. The Center for Science in the Public Interest is threatening to sue the maker of One-A-Day multivitamins if the company doesn’t cease claiming that selenium, a mineral in the pills, may cut men’s risk of prostate cancer.
Researchers halted a federally funded study of selenium’s ability to protect against prostate cancer last year when the mineral showed no effect and some men taking it developed diabetes.
Yet Bayer claims in ads, including this Web site for its Men’s Health Formula multivitamin, that “emerging research suggests Selenium may reduce the risk of prostate cancer.” Indeed, CPSI also asked the Federal Trade Commission to require Bayer to run corrective ads, given the impression made by at least 11 television ads and nine radio ads touting prostate protection.
A Bayer spokeswoman told the Associated Press that the company stands “behind all claims made in support of our products.”